Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Print PDF (257K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (51)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Kantor, R.
Right arrow Articles by Shafer, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kantor, R.
Right arrow Articles by Shafer, R. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2001, Vol. 29, No. 1 296-299
© 2001 Oxford University Press

Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs

Rami Kantor1, Rhoderick Machekano1, Mathew J. Gonzales1, Kathryn Dupnik1, Jonathan M. Schapiro1,2 and Robert W. Shafer1,*

1Division of Infectious Diseases, Stanford University Medical Center, Stanford, CA 94305, USA and 2National Hemophilia Center, Tel-Hashomer Hospital, Tel Aviv, Israel

The HIV Reverse Transcriptase and Protease Sequence Database is an on-line relational database that catalogs evolutionary and drug-related sequence variation in the human immunodeficiency virus (HIV) reverse transcriptase (RT) and protease enzymes, the molecular targets of anti-HIV therapy (http://hivdb.stanford.edu). The database contains a compilation of nearly all published HIV RT and protease sequences, including submissions from International Collaboration databases and sequences published in journal articles. Sequences are linked to data about the source of the sequence sample and the antiretroviral drug treatment history of the individual from whom the isolate was obtained. During the past year 3500 sequences have been added and the data model has been expanded to include drug susceptibility data on sequenced isolates. Database content has also been integrated with didactic text and the output of two sequence analysis programs.

* To whom correspondence should be addressed. Tel: +1 650 725 2946; Fax: +1 650 723 8596; Email: rshafer{at}cmgm.stanford.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BioinformaticsHome page
K. Deforche, R. Camacho, K. Van Laethem, P. Lemey, A. Rambaut, Y. Moreau, and A.-M. Vandamme
Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment
Bioinformatics, January 1, 2008; 24(1): 34 - 41.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
K. Deforche, T. Silander, R. Camacho, Z . Grossman, M. A. Soares, K. Van Laethem, R. Kantor, Y. Moreau, A.-M. Vandamme, and on behalf of the non-B Workgroup
Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance
Bioinformatics, December 15, 2006; 22(24): 2975 - 2979.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
L. M. F. Gonzalez, R. S. Aguiar, A. Afonso, P. A. Brindeiro, M. B. Arruda, M. A. Soares, R. M. Brindeiro, and A. Tanuri
Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
J. Gen. Virol., May 1, 2006; 87(Pt 5): 1303 - 1309.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. A. Smith, D. J. Anderson, and B. D. Preston
Purifying Selection Masks the Mutational Flexibility of HIV-1 Reverse Transcriptase
J. Biol. Chem., June 18, 2004; 279(25): 26726 - 26734.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Z. Grossman, E. E. Paxinos, D. Averbuch, S. Maayan, N. T. Parkin, D. Engelhard, M. Lorber, V. Istomin, Y. Shaked, E. Mendelson, et al.
Mutation D30N Is Not Preferentially Selected by Human Immunodeficiency Virus Type 1 Subtype C in the Development of Resistance to Nelfinavir
Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2159 - 2165.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Paolucci, F. Baldanti, M. Zavattoni, and G. Gerna
Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV-1 variants
J. Antimicrob. Chemother., May 1, 2004; 53(5): 766 - 771.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
B. C. Logsdon, J. F. Vickrey, P. Martin, G. Proteasa, J. I. Koepke, S. R. Terlecky, Z. Wawrzak, M. A. Winters, T. C. Merigan, and L. C. Kovari
Crystal Structures of a Multidrug-Resistant Human Immunodeficiency Virus Type 1 Protease Reveal an Expanded Active-Site Cavity
J. Virol., March 15, 2004; 78(6): 3123 - 3132.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
N. T. Parkin, N. S. Hellmann, J. M. Whitcomb, L. Kiss, C. Chappey, and C. J. Petropoulos
Natural Variation of Drug Susceptibility in Wild-Type Human Immunodeficiency Virus Type 1
Antimicrob. Agents Chemother., February 1, 2004; 48(2): 437 - 443.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
S.-Y. Rhee, M. J. Gonzales, R. Kantor, B. J. Betts, J. Ravela, and R. W. Shafer
Human immunodeficiency virus reverse transcriptase and protease sequence database
Nucleic Acids Res., January 1, 2003; 31(1): 298 - 303.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Paolucci, F. Baldanti, M. Zavattoni, G. Comolli, N. Labo, S. Menzo, M. Clementi, and G. Gerna
Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients
J. Antimicrob. Chemother., January 1, 2003; 51(1): 135 - 139.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
G. H. Kijak, V. Simon, P. Balfe, J. Vanderhoeven, S. E. Pampuro, C. Zala, C. Ochoa, P. Cahn, M. Markowitz, and H. Salomon
Origin of Human Immunodeficiency Virus Type 1 Quasispecies Emerging after Antiretroviral Treatment Interruption in Patients with Therapeutic Failure
J. Virol., June 14, 2002; 76(14): 7000 - 7009.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
R. W. Shafer
Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance
Clin. Microbiol. Rev., April 1, 2002; 15(2): 247 - 277.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. A. Winters and T. C. Merigan
Variants Other than Aspartic Acid at Codon 69 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene Affect Susceptibility to Nucleoside Analogs
Antimicrob. Agents Chemother., August 1, 2001; 45(8): 2276 - 2279.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.